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Abstract The hypothesis was tested that oral antibiotic
treatment in children with acute pyelonephritis and scintig-
raphy-documented lesions is equally as efficacious as
sequential intravenous/oral therapy with respect to the
incidence of renal scarring. A randomised multi-centre trial
was conducted in 365 children aged 6 months to 16 years
with bacterial growth in cultures from urine collected by
catheter. The children were assigned to receive either oral
ceftibuten (9 mg/kg once daily) for 14 days or intravenous
ceftriaxone (50 mg/kg once daily) for 3 days followed by
oral ceftibuten for 11 days. Only patients with lesions
detected on acute-phase dimercaptosuccinic acid (DMSA)
scintigraphy underwent follow-up scintigraphy. Efficacy was
evaluated by the rate of renal scarring after 6 months on
follow-up scintigraphy. Of 219 children with lesions on
acute-phase scintigraphy, 152 completed the study; 80 (72
females, median age 2.2 years) were given ceftibuten and 72
(62 females, median age 1.6 years) were given ceftriaxone/
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ceftibuten. Patients in the intravenous/oral group had
significantly higher C-reactive protein (CRP) concentrations
at baseline and larger lesion(s) on acute-phase scintigraphy.
Follow-up scintigraphy showed renal scarring in 21/80
children treated with ceftibuten and 33/72 with ceftriaxone/
ceftibuten (p=0.01). However, after adjustment for the
confounding variables (CRP and size of acute-phase lesion),
no significant difference was observed for renal scarring
between the two groups (p=0.2). Renal scarring correlated
with the extent of the acute-phase lesion (r=0.60, p<0.0001)
and the grade of vesico-ureteric reflux (r=0.31, p=0.03), and
was more frequent in refluxing renal units (p=0.04). The
majority of patients, i.e. 44 in the oral group and 47 in the
intravenous/oral group, were managed as out-patients. Side
effects were not observed. From this study, we can conclude
that once-daily oral ceftibuten for 14 days yielded compa-
rable results to sequential ceftriaxone/ceftibuten treatment in
children aged 6 months to 16 years with DMSA-documented
acute pyelonephritis and it allowed out-patient management
in the majority of these children.
Keywords Ceftibuten . Child . Pyelonephritis .
Scintigraphy . Out-patient
Abbreviations
CRP C-reactive protein
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Introduction
In infants and young children, upper and lower urinary tract
infections are common [1], and a febrile urinary tract infection
is considered to be an upper urinary tract infection (i.e.
pyelonephritis). Up to two thirds of children with acute
pyelonephritis show a lesion (defect) on technetium-
99m-labelled dimercaptosuccinic acid (DMSA) scintigraphy
during the acute phase [5, 14, 21, 25]. Only these children
develop post-infectious renal scarring and the incidence is 29–
60% [5, 15, 21, 24, 30, 35]. Long-term follow-up of children
with renal scarring showed a significant reduction of renal
function [20, 32, 33]. In contrast, children with a febrile
urinary tract infection without lesion on acute-phase DMSA
scintigraphy did not develop renal scarring [14, 15, 30].
Although the recommended initial treatment for infants
and young children with pyelonephritis is the intravenous
administration of antibiotics [1, 5, 6, 8], we hypothesised that
oral antibiotics are equally as efficacious as sequential
intravenous/oral treatment with respect to the incidence of
renal scarring 6 months after acute pyelonephritis with
scintigraphy-documented acute lesions. Several lines of
evidence support our hypothesis. The prevalence of bacter-
aemia in pyelonephritis is 6.1–22.7% in infants younger than
2 months of age [7, 25] and 9.3% in infants younger than 6
months [2]. In contrast, children older than 6 months of age
either never have bacteraemia [2] or only rarely show signs
of bacteraemia [25]. Thus, oral antimicrobial therapy of
acute pyelonephritis appeared to be a safe option, particu-
larly for children older than 6 months of age. Indeed, the
results from two prior prospective trials suggested that acute
pyelonephritis in children could be treated with oral anti-
biotics [14, 21]. Two additional aspects need consideration.
First, it has to be shown that the oral route is as efficacious
as the parenteral route also in patients at the highest risk for
renal scarring, i.e. children with systemic inflammation (high
C-reactive protein [CRP]) and initial scintigraphic lesions.
Second, oral treatment might allow full out-patient manage-
ment with major benefits to patients and parents. Ceftibuten,
an oral cephalosporin, was deliberately chosen for three
reasons: (i) good antimicrobial activity, (ii) lack of resistance
against pathogens of community-acquired urinary tract
infection and (iii) its long half-life, allowing once-daily oral
dosing [4, 19, 23, 34].
To test our hypothesis, we conducted a prospective
randomised controlled multi-centre trial to compare the effect
of oral treatment with once-daily ceftibuten for 14 days with
the effect of the sequential intravenous/oral regimen (3 days of
intravenous treatment with ceftriaxone, followed by 11 days
with oral cephalosporin) [5]. Where it was in accordance
with the local hospital guidelines, patients were planned to
be treated as out-patients, since oral and out-patient
management might reduce the burden on hospital staff and
costs. Only children older than 6 months of age with acute
pyelonephritis and acute lesions on DMSA scintigraphy [10,
11, 29]—those at highest risk for sequelae, i.e. renal
scarring—were included.
Methods
Five Swiss paediatric hospitals collaborated in a prospec-
tive, investigator-initiated clinical trial to compare the
effects of oral and sequential intravenous/oral antibiotic
regimens in children with pyelonephritis and acute lesions
on DMSA scintigraphy. Patients were recruited from 1 July
2001 to 30 April 2004 and follow-up ended on 31
December 2004. The study was approved by the national
agency for therapeutic products (Swissmedic) and the local
ethical committees of all of the participating centres.
Written informed consent was obtained from at least one
parent of each patient. The study was carried out indepen-
dently of the financial supporter. Financial industry support
for the central collection and analysis of data was sought
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only after the study had been approved by the national and
local authorities.
Patient recruitment
Patients aged 6 months to 16 years with acute community-
acquired pyelonephritis treated at the University Children’s
Hospitals of Zurich, Geneva and Basle or in the depart-
ments of paediatrics of the hospitals of Winterthur and
Zurich-Triemli, were eligible. Laboratory tests on admis-
sion included blood count, CRP, plasma creatinine, blood
cultures, urinary dipstick and/or microscopic urinalysis (cell
count in non-centrifuged urine), and urine culture. The urine
samples were collected by bladder catheterisation. The
diagnosis of acute pyelonephritis was considered to be
probable in children with fever (rectal temperature >38°C or
axillary temperature >38.5°C), an abnormal urinary dipstick
test (leukocyte esterase ≥1+, or nitrite positive) or microscopic
urinalysis (pyuria with ≥10 white blood cells/μl), and serum
CRP concentration >10 mg/l (normal <4 mg/l). Additional
clinical signs were not mandatory (e.g. abdominal or flank
pain in children old enough to report pain accurately,
irritability, vomiting, diarrhoea or feeding problems in
infants). Positive urine culture was defined as growth ≥104
colony-forming units/ml of a single bacterium. Patients
known to have isolated vesico-ureteric reflux (VUR),
megaureter or duplex kidney, independently of antibiotic
prophylaxis (e.g. cotrimoxazole, trimethoprim or nitrofur-
antoin) were also included. The exclusion criteria were age
<6 months, antibiotic pre-treatment of acute infection, other
abnormalities of the urinary tract, known impaired renal
function, patients on immunosuppressive therapy and known
hypersensitivity to cephalosporins. Patients were also ex-
cluded at the discretion of the treating physician if the
clinical condition suggested septicaemia or if other reasons
precluded oral treatment.
Randomisation
Each centre was provided, as many times as necessary, with
blocks of 24 sealed envelopes containing an equal number of
assignments for the two antibiotic regimens. A statistician
provided the computer-generated code and an independent
clerk sealed and bundled the opaque envelopes, so that the
person enrolling the patient into the study would not have
known the patient’s assignment. Patients were locally
randomised at the time of admission. For practical reasons,
all patients with a presumed clinical diagnosis of probable
pyelonephritis were randomised at their first consultation in
the emergency unit (i.e. before the results of the urine culture
and DMSA scintigraphy were available). Thus, stratification
for potentially confounding variables (e.g. grade of inflam-
mation [CRP], size of lesion on acute-phase DMSA scintig-
raphy and the presence/grade of VUR) was not performed.
Only patients with acute pyelonephritis and lesions on acute-
phase scintigraphy, as assessed by the treating physicians,
underwent a follow-up scintigraphy.
Antimicrobial therapy and prophylaxis
Antibiotic therapy was started immediately after the urine and
blood samples had been analysed. For the “oral-only group,”
patients received 9 mg/kg body weight of ceftibuten [34]
(Cedax, Essex, Lucerne, Switzerland; in Switzerland, it is
licensed for children ≥6 months of age) orally twice on the
first day and once daily thereafter for 14 days. In the
“intravenous/oral group,” patients received 50 mg/kg cef-
triaxone (Rocephin®, Roche, Basle, Switzerland) intrave-
nously once daily for 3 days and then 9 mg/kg body weight
of ceftibuten orally for 11 days. Ceftibuten is commercially
available in most European countries and in the US.
Before starting the clinical study, the antimicrobial
susceptibility of Gram-negative bacteria, isolated from
positive urine cultures consecutively collected from in-
patients and out-patients at one centre (University Child-
ren’s Hospital Zurich), was tested. Of 285 Gram-negative
bacterial isolates, 243 were sensitive to ceftibuten and
ceftriaxone; only Pseudomonas aeruginosa (n=27) and
Enterobacter cloacae (n=15), two unusual pathogens in
community-acquired pyelonephritis, were resistant. Only
63% and 41% of the isolates were sensitive to amoxicillin/
clavulanic acid and amoxicillin, respectively.
Deviation from the assigned antimicrobial treatment
regimen was permitted in the following events: (i) clinical
deterioration as assessed by the treating physician, (ii)
presumed side effects of the study drugs, (iii) resistance of
bacteria grown in initial urine culture to the study anti-
biotics and (iv) bacterial growth on follow-up urine culture
on days 3–4.
All patients were followed at each study centre at least
until day 3; patients with persistent fever at day 3 were
followed until defervescence. The patients were then
followed clinically by their local paediatrician, who in-
formed the study centres in case of recurrent urinary tract
infection. At the end of the 14-day treatment, antibiotic
prophylaxis was started either with cotrimoxazole (12–
18 mg/kg body weight in one or two doses daily) or
nitrofurantoin (1–1.5 mg/kg body weight in one or two
doses daily) according to the Swiss guidelines [13] and was
discontinued only if voiding cystourethrography showed
neither VUR nor other malformations of the urinary tract.
Outcome measures
Urine culture and serum CRP were repeated on days 3–4 of
treatment. Renal ultrasound was done within 24 hours,
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whereas renal DMSA scintigraphy was performed within
5 days, since the nuclear medicine department does not offer
DMSA scanning 7 days a week. Thus, some minor lesions
might become invisible between the onset of antibiotic
therapy and scanning, leading to false-negative DMSA
scintigraphy results. Of the children enrolled, only those with
lesions on acute-phase scintigraphy were followed with a
second scintigraphy (see below). Investigations were com-
pleted 2–8 weeks after the acute episode by voiding
cystourethrography (at least two fillings were performed) to
detect VUR (grade I–V). Specimens for urine culture were
obtained at the voiding cystourethrography and when the
children had fever or symptoms of urinary tract infection. The
study patients were followed at voiding cystourethrography
and after 6 months at follow-up scintigraphy. Parents were
asked whether their child had had fever or recurrence of
urinary tract infection and whether the prophylaxis had been
given as prescribed. In addition, the safety and convenience of
treatment were evaluated in terms of the discontinuation of
therapy and the incidence of side effects.
The primary end point was—only in patients with
lesions on acute-phase scintigraphy—the development of
renal scarring in both groups (oral and intravenous/oral)
after at least 6 months, documented by follow-up DMSA
scintigraphy. The 6-month interval between the acute-phase
and follow-up scintigraphy was chosen because acute
pyelonephritic defects can persist for up to 5 months [16].
The secondary end point was the effect of VUR on the
development of renal scarring.
Renal DMSA scintigraphy
Scintigraphy was performed 3 hours after the intravenous
injection of 99mTc-DMSA (MallinckrodtMedical B.V., Petten,
Netherlands). The administered dose was weight-adjusted
according to the recommendations of the Pediatric Committee
of the EANM (http://www.eanm.org/scientific_info/guidelines/
gl_paed_dmsa_scin.php?navId=54), with a minimal dose of
15 MBq and a maximal dose of 100 MBq. Two (one anterior
and one posterior view) to six views (one anterior, one
posterior, two posterior oblique and two anterior oblique
views) were obtained, but tomography was not systematically
performed. Each kidney (i.e. renal unit) was assessed
separately. Images were acquired on dual-head gamma
cameras (Zurich: Body Scan, Siemens, Erlangen, Germany;
Zurich-Triemli: Prism 2000 XP with pinhole collimator,
Philips (former Picker), Eindhoven, Netherlands; Winterthur:
E Cam, Siemens, Erlangen, Germany; Basel: Axis, Philips,
Eindhoven, Netherlands) or a triple-head gamma camera
(Geneva: Toshiba GCA-9300 A/HG, Toshiba Medical Sys-
tems, Tokyo, Japan).
Two paediatric nuclear medicine experts, unaware of the
treatment assigned to the patients, independently interpreted
all of the initial and follow-up scintigraphies. Disagree-
ments were resolved by joint evaluation. The progression of
renal lesions was assessed by topographic analysis of each
lesion. Renal scars in the follow-up scintigraphy were
defined as persistent or partially reversible lesions at the
same location of the lesion in the acute-phase scintigraphy.
The relative size of each lesion was estimated by relating
the surface of the lesion to the surface of the kidney in the
view of the scintigraphy where the size of the lesion was
most pronounced. The grading of the size of the lesion(s)
was as follows: grade 0=normal, I=1–9%, II=10–24%,
III=25–50% and IV=>50%.
Statistical analysis
On the basis of our previous study [5], we estimated that
the incidence of renal scarring was approximately 35%.
This is a non-inferiority trial where a maximal difference
of 20% between the percentages of renal scarring of the
two groups is considered to be acceptable. For a power of
90% and a type 1 error level of 5% (two tailed), the
sample size should be 98 children completing the study in
each group; for a power of 80%, the sample size should be
at least 71 children in each group (Pass 6.0, NCSS,
Kaysville, UT, USA). The Mann-Whitney U-test was used
for non-parametric comparison between the two groups.
Proportions between the groups were compared by the χ2-
test.
Despite randomisation, the oral and intravenous/oral
groups showed statistically significant differences in CRP
concentration at baseline and size of the initial lesion on
acute-phase DMSA scintigraphy. Therefore, to compare
proportions between groups, logistic regression was used,
and the proportions were adjusted for these two confound-
ing variables. Spearman rank correlation was calculated
between the size of renal scarring and the CRP concen-
tration at baseline, the size of the lesion on acute-phase
scintigraphy and the grade of VUR. A p-value < 0.05 was
considered to be statistically significant (software: S-Plus
7.0 for Windows, Insightful, Seattle, WA).
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Results
Patient data
A total of 365 patients were randomised (Fig. 1). No acute-
phase scintigraphy was available for 19 (5%) patients and
they were excluded. Consent was withdrawn in 17 patients,
including one patient in the oral group with a protocol
deviation. Two further patients were excluded due to
protocol violation; one was given cefixime instead of
ceftibuten and the other was administered medication only
after day 3.
Acute-phase DMSA scintigraphy was performed in 346
patients; 219 patients (63%) showed one or more lesions
and were planned to have follow-up scintigraphy. Of these,
67 patients (31%) had no secondary scintigraphy and did
not complete the study, including four patients who
deviated from the assigned antimicrobial regimen for
medical reasons and nine patients undergoing a subsequent
operation (for details, see Patients not completing the
study). Under the study protocol, 127 patients with normal
acute-phase scintigraphy had no follow-up.
The cohort completing the study with follow-up scintigra-
phy consisted of 152 patients with acute pyelonephritis and
lesions on acute-phase scintigraphy. There were 80 patients in
the oral group and 72 patients in the intravenous/oral group
(Fig. 1). The clinical and laboratory characteristics at
baseline (Table 1) and the prevalence of VUR (Table 2)
did not significantly differ between the two groups, except
for serum CRP concentration at baseline (p=0.04). All
patients had either an abnormal urinary dipstick test or
pyuria with ≥10 white blood cells/μl. Plasma creatinine was
normal in all participants. Escherichia coli were the
predominant isolated pathogen (137/152: 90%); Proteus
spp., Klebsiella pneumoniae and Enterococcus spp. were
isolated in only a few cases (Table 1). All isolated bacteria
except Enterococcus spp. were sensitive to both ceftibuten
and ceftriaxone.
The clinical course was comparable in both groups
(Table 1). By day 3, approximately 90% of the patients
were afebrile and CRP levels decreased to about 60% in
both groups; seven and eight patients from the oral and
intravenous/oral group, respectively, had persistent fever. In
two of them (both from the oral group), the general
condition did not improve and therapy was switched to
intravenous treatment with amoxicillin/clavulanic acid and
ceftriaxone. One patient in the intravenous/oral group had
E. coli bacteraemia; the clinical course was uneventful
without changing the therapeutic regimen. Urine culture
grew cephalosporin-resistant Enterococcus spp. in three
patients in the intravenous/oral group. At day 3, the urine
was sterile in all of them and two patients were afebrile.
Thus, antimicrobial therapy was not changed. Urine
cultures obtained from every patient on days 3–4 of
treatment were all sterile. Both antimicrobial regimens
were well tolerated and no side effects (e.g. skin rash,
diarrhoea and gall or kidney stones) were observed.
All 92 patients (61% of the study cohort) at the
University Children’s Hospitals Zurich and Geneva were
treated as out-patients. The majority of patients from the
other centres were hospitalised for an average of 3 days.
Acute-phase DMSA scintigraphy
Eight patients from each group had acute-phase bilateral
lesions, resulting in 88 and 80 affected renal units in the
oral and intravenous/oral groups, respectively (Table 3). In
the majority of renal units, the size of the acute lesion was
grade I or II. Extensive lesions (grade III and IV) were less
frequent in the oral group than in the intravenous/oral group
(11/160 vs. 22/144 renal units; p=0.03; χ2-test).
Renal scarring on follow-up DMSA scintigraphy
Among the 152 children, 54 developed renal scarring,
including 21 patients from the oral group and 33 (46%) from
the intravenous/oral group (Table 3). Among patients with
bilateral acute-phase lesions, none from the oral group but
three of eight patients from the intravenous/oral group
developed bilateral scars. All scars were localised to the site
of the acute-phase lesion(s). Renal scarring correlated with the
size of the acute renal lesion (r=0.60, p<0.0001; Table 3).
After statistical adjustment for the two confounding variables
(i.e. CRP concentration at baseline and size of the acute-phase
scintigraphic lesion), there was no significant difference
between the percentages of renal scarring in the two groups,
either expressed per patient or per renal unit (adjusted p-
values; Table 3). All three patients from the intravenous/oral
group with Enterococcus spp. whose urine had became sterile
at day 3 and both patients from the oral group with protocol
deviation developed renal scarring.
The prevalence of VUR did not significantly differ
between the two groups. VUR was present in 93 (31%) of
304 renal units with grades I–II, III and IV in 71, 15 and 7
units, respectively (Table 2). Scarring in patients with
unilateral VUR was always restricted to the refluxing unit.
The correlation between VUR and renal scarring was
analysed in a double manner (Table 4). If VUR and scarring
were expressed per patient, renal scarring was not signifi-
cantly different in patients with and without VUR. However,
if VUR and scarring were analysed per renal unit, scarring
was more frequent in refluxing units (p=0.04; χ2-test). In
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addition, scarring was correlated with the grade of VUR (r=
0.31, p=0.03). All seven renal units with grade IV VUR
developed scars and renal units with grade III or IV VUR
(11/22; 50%) had significantly more scarring compared to
renal units with grade I–II VUR (16/71; 23%: p=0.02;
χ2-test).
The frequency of renal scarring was not different
between infants <1 year of age (14/46) and older children
(40/106). In addition, the frequency of renal scarring did
not differ between the two centres conducting out-patient
management only and the three centres carrying out in-
patient management (Table 5). In addition, there was no
difference in the frequency of scarring among the five
recruitment centres (data not shown).
Urinary tract infection was reported in 27 patients (18%)
before entry into the study, though it was not specified as
cystitis or pyelonephritis (Table 1). Three of 14 patients
from the oral group showed renal scarring, compared with
seven of 13 patients from the oral/intravenous group. Six
patients had a recurrent febrile urinary tract infection
between the acute-phase and follow-up scintigraphy. Both
patients from the oral group had no scarring. In contrast, all
Randomisation: n = 365 
Oral: n = 175; intravenous/oral: n = 190 
Drop out: No acute-phase scintigraphy: n = 19
- Oral group: n = 11 
- Intravenous/oral group: n = 8
n = 17: consent withdrawn, including protocol deviation (n = 1) 
n = 2: protocol violation
Patients undergoing acute-phase scintigraphy: n = 346 
Oral: n = 164; intravenous/oral : n = 182 
Drop out: Normal acute-phase scintigraphy: n = 127 (37% of 346) 
- Oral group: 54/164 (33%) 
- Intravenous/oral group: n = 73/182 (40%) 
Patiens with lesion on acute-phase scintigraphy: n = 219 (63% of 346) 
Oral: n = 110; intravenous/oral: n = 109 
Drop out: No follow-up scintigraphy: n = 67 (31% of 219) 
- Oral group: n = 30 
- Intravenous/oral group: n = 37 
n = 58: consent withdrawn, including protocol deviation (n = 4) 
n = 9: subsequent operation
Ultimate study cohort with follow-up scintigraphy: n = 152 (69% of 219) 
Zurich: n = 56 (28: oral – 28: intravenous/oral) 
Geneva: n = 36 (16 – 20) 
Winterthur: n = 32 (19 – 13)
Zurich-Triemli: n = 20 (12 – 8) 
Basle: n = 8 (5 – 3)  
Oral group: n = 80 Intravenous/oral: n = 72
Fig. 1 Randomisation and pa-
tient flow chart
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four patients from the intravenous/oral group had scars at
the same location as the lesions on acute-phase scintigra-
phy. As it is difficult, if not impossible, to distinguish
between fresh lesions and old scars, additional analysis was
undertaken after the exclusion of the 33 patients with
previous or recurrent pyelonephritis. Renal scarring was not
significantly different between the patients in the oral group
(18/64) and in the intravenous/oral group (22/55; p=0.17).
Patients not completing the study
Of 365 randomised patients, 86 failed to adhere to the
protocol and did not complete the study; 19 patients had no
acute-phase scintigraphy and 67 patients with lesions on
acute-phase scintigraphy had no follow-up scintigraphy
(Fig. 1). Five patients deviated from the assigned treatment
regimen for medical reasons. One patient was randomly
placed in the oral group and switched to intravenous
therapy due to recurrent vomiting; acute-phase scintigraphy
was not performed but scintigraphy, performed after
antireflux surgery 2 years later, was normal. Four patients
with lesions on acute-phase scintigraphy showed persistent
fever beyond day 3 without apparent improvement of the
general condition. One patient from the oral group was
switched to intravenous meropenem. Two patients from the
intravenous/oral group were maintained on ceftriaxone for
7 days. Another patient from the intravenous/oral group
with Enterococcus spp. in urine culture was switched to
amoxicillin/clavulanic acid. The parents withdrew consent
for follow-up scintigraphy in those four patients and in 54
additional patients. Nine patients underwent surgery; ureter-
ocystoneostomy in five patients with VUR, pyeloplasty in
three patients with pyeloureteric junction obstruction and
nephrectomy of a multi-cystic dysplastic kidney in one
patient. None of these children had follow-up scintigraphy.
In one centre (University Children’s Hospital Zurich), all
eligible patients were recorded in a “log book” and any
reasons for refusal or withdrawal were recorded. There
were 292 children with a febrile urinary tract infection, of
whom, 40 patients were excluded in accordance with the
exclusion criteria. Of the 252 eligible study candidates, 125
(50%) could not be randomised for two reasons: 65 Swiss
patients whose parents did not consent and 60 immigrants
whose parents had a language barrier, rendering informed
consent impossible. Thus, 127 patients were randomised;
48 patients were not enrolled because no acute-phase
scintigraphy had been performed (parental withdrawal of
consent: n=10; protocol violation: n=1) or the acute-phase
scintigraphy was normal (with bacteriuria: n=29; with
negative urine culture: n=8), 23 patients with acute-phase
lesions had no follow-up scintigraphy and 56 patients
completed the study.
Table 1 Baseline characteristics of 152 children with lesions on
acute-phase dimercaptosuccinic acid (DMSA) scintigraphy
Characteristics Oral group,
n=80
Intravenous/oral
group, n=72
Sex
Male 8 10
Female 72 62
Age (years)
Median 2.2 1.6
Interquartile range 0.9–4.9 1.0–4.4
Previous urinary tract
infections
None 66 59
≥1 14 13
Fever (≥38.5°C) before
treatment (days)
Median 3 2.5
Fever on day 3 7 8
C-reactive protein
(CRP, mg/l)
at baseline: median (range) 100 (8–327)a 128 (12–378)a
at day 3: median (range) 59 (10–404) 75 (12–378)
Bacterial urinary pathogens
Escherichia coli 73 64
Proteus spp. 1 1
Klebsiella pneumoniae 1 0
Enterococcus spp. 0 3
Data not available 5 6
Positive blood cultures
(E. coli)
0 1
a p=0.04, Mann-Whitney test
Table 2 Associated renal and urological anomalies
Anomalies Oral group,
n=80
Intravenous/oral group,
n=72
Vesico-ureteric reflux
(VUR)
In patientsa 29 35
Unilateral 14 21
Bilateral 15 14
In renal unitsb 44 (28%) 49 (34%)
Left 26 29
Right 18 20
Grade of VUR
(renal units)
I–II 34 37
III 7 8
IV 3 4
Hydronephrosis 1 0
Hypospadia glandis 0 1
Duplex kidney and
ureterocele
1 0
a p=0.17; b p=0.27 (comparison between the groups)
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Discussion
This prospective multi-centre randomised trial focussed on
children with community-acquired acute pyelonephritis and
renal lesions on acute-phase DMSA scintigraphy, i.e.
patients at risk for renal scarring. In patients aged 6 months
to 16 years, we showed that oral treatment with once-daily
ceftibuten is safe and is equally as efficacious with respect
to renal scarring after 6 months when compared with a
sequential intravenous/oral regimen. The oral antimicrobial
was well-tolerated and side effects, including skin rash,
diarrhoea or gall bladder or kidney stones, were not
observed. Thus, this study identifies a treatment modality
for acute pyelonephritis in children that offers the benefits
of entire out-patient management.
The study was designed to compare the efficacy of oral
with sequential intravenous/oral antimicrobial treatment for
children with pyelonephritis at risk of renal scarring.
Patients were randomised for the treatment regimen before
scintigraphic lesions were verified for two reasons: (i) only
children with lesions in acute-phase scintigraphy are likely
to develop renal scars [14, 15, 30] (ii) acute-phase
scintigraphy cannot be performed immediately after the
diagnosis of acute pyelonephritis. However, to improve the
diagnostic accuracy of acute pyelonephritis, DMSA scin-
tigraphy is ideally carried out within two days. In the
future, magnetic resonance imaging (MRI) might offer both
the use of non-ionizing radiation and a better distinction
between acute lesion and scar [18].
The presence of renal scars is a surrogate outcome.
Although only a few studies have analysed the long-term
outcome, renal scars can result in significant sequelae [20,
32, 33]. The follow-up of children with renal scarring for
16–26 years after childhood pyelonephritis showed a
significant reduction of individual glomerular filtration rate
in the unilaterally scarred kidney [32, 33]. In addition, the
Table 3 Acute-phase lesions and scarring in renal units on DMSA scintigraphy
Characteristics Oral group, n=160 renal units Intravenous/oral group, n=144 renal units Adjusted p-value*
Acute lesion Scarring Acute lesion Scarring
Renal units: acute lesions 88a 80a
Scarring
Patients 21 33 0.2
Renal units (% of all units) 21 (13%) 36b (25%) 0.5
Renal units: acute lesion grade I 49 29
Scarring 4 3
Renal units: acute lesion grade II 28 29
Scarring 11 13
Renal units: acute lesion grade III 9 17
Scarring 5 15
Renal units: acute lesion grade IV 2 5
Scarring 1 5
a Eight patients in each group with acute-phase bilateral lesions
b Three patients with bilateral scarring
*p-values adjusted for CRP concentration at baseline and size of lesion on acute-phase scintigraphy
Table 4 Renal scarring and vesico-ureteric reflux (VUR)
Characteristics Oral group, n=80 Intravenous/oral group, n=72 p-value
Scarring in patients with reflux 9/29 18/35 n.s.
Scarring in patients without reflux 12/51 15/37 n.s.
All 152 patients n.s.
Scarring in patients with reflux: 27/64 vs. without reflux: 27/88
Scarring in renal units with ipsilateral reflux n.s.
All units 9/44 18/49
Left unit 8/26 11/29
Right unit 1/18 7/20
All 304 renal units 0.04
Scarring in units with reflux: 27/93 vs. without reflux: 30a/211
a Three patients with bilateral scarring in non-refluxing units
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long-term outcome at a mean age of 41 years (and mean
follow-up of 37 years) in children with both pyelonephritis
and VUR showed a lowered glomerular filtration rate (83%
of patients), hypertension (50%) and proteinuria (25%) in
patients with bilateral scars [20]. An increased tendency for
hypertension was also found in patients with unilateral
scarring [20].
The proportions of renal scarring in patients (oral group:
26%; intravenous/oral group: 46%) were comparable with
previous scintigraphy investigations that documented renal
scarring in 29–60% of children after acute pyelonephritis
[5, 15, 16, 21, 24, 30, 31, 35]. These results indicate that
mere oral ceftibuten therapy is as efficacious as parenteral
therapy, i.e. a 3-day or even a 10-day course of intravenous
antibiotic therapy with respect to renal scarring. However,
antibiotic therapy either intravenous or oral is not able to
prevent renal scarring in a substantial proportion of children
with pyelonephritis. The percentage of renal scarring in our
study appeared to be lower in the oral treatment group than
in the intravenous/oral group. Yet, despite randomisation,
the two groups differed significantly in the number of
patients with previous and recurrent infections, CRP
concentration at baseline and the size of the lesion in
acute-phase scintigraphy. The latter variable has a signifi-
cant effect on the evolution of renal scarring, as observed in
our previous study [5]. After adjustment for these con-
founding variables, the final analysis showed a similar
frequency of renal scarring in both groups. Children
aged >1 year did not develop scars more frequently than
children <1 year of age. This is in contrast to previous
studies, including our own [5, 15, 24].
There was no significant difference of renal scarring
between in-patients and out-patients in both the oral and the
intravenous/oral groups. Also taking into consideration that
allocation to in-patient or out-patient treatment was deter-
mined by local hospital guidelines and not by random-
isation, this finding is valid and reliable, as the treatment of
every patient was guided by a defined protocol. Thus, if
out-patient treatment is chosen, clinical evaluation and
urinalysis at day 3 and day 14 are recommended. If the
patient is afebrile and urinalysis is normal, routine follow-
up urine culture is not mandatory. Oral out-patient
management might reduce the costs, though this was not
formally evaluated here.
In this study, renal scarring correlated significantly with
the VUR per renal unit (but not per patient) and the grade
of VUR, in particular, grades III or IV VUR. Renal scarring
in patients with unilateral VUR was always restricted to the
refluxing unit. Published studies on the effects of VUR on
renal scarring are controversial. Some studies showed a
significant influence [12, 24, 26], while others did not [5,
22]. There were, however, methodological inconsistencies.
For example, not all studies discriminated between lower
and upper urinary tract infection or between VUR per
patient and per renal unit.
Almost all pathogens isolated in this study of acute
community-acquired pyelonephritis were E. coli susceptible
to cephalosporins. Thus, antimicrobial treatment with the
chosen cephalosporin is safe. This is of considerable
relevance, given that the prevalence of E. coli resistant to
aminopenicillins may be up to 50% [27]. The specific
advantage of the oral cephalosporin ceftibuten for out-
patient management is its once-daily oral dosing, based on
a long T1/2 with plasma concentrations above minimal
inhibitory concentration for >16 hours; it has an excellent
oral bioavailability and 60–70% of the drug is excreted in
the urine. The recommended dose is 9 mg/kg body weight
given once daily [4, 17, 23, 34]. Side effects in this and
other studies are rare [28, 34] and ceftibuten has been
previously examined in children with urinary tract infection
[3, 31]. Infections with intrinsically cephalosporin-resistant
Enterococcus spp. in this study were rare (4/365; 1%); in
three of these cases, the urine was sterile on day 3,
suggesting a good clinical response and, therefore, not
urging the treating physicians to change therapy. Neverthe-
less, all three patients developed renal scars. Thus, patients
with acute pyelonephritis treated with a cephalosporin
should be switched to aminopenicillin upon the growth of
enterococci in urine cultures.
Our results are in agreement with two recent prospective
trials which suggested that acute pyelonephritis can be
treated with oral antibiotics. In the study by Montini et al.
[21], amoxicillin/clavulanic acid was given for 10 days to
135 children aged 1 month to 7 years. Renal scarring
developed in 26/96 patients (28%), with lesions on acute-
phase scintigraphy comparable to the 26% found among
children with oral treatment in our study and in earlier
studies [5, 15, 16, 24, 30, 35]. However, the high
Table 5 Renal scarring in patients with out-patient and in-patient management
Management All patients Oral group Intravenous/oral group
n Scars n Scars n Scars
Out-patient 92 35 44 14 48 21
In-patient 60 19 36 6 24 13
χ2-test, p-value 0.5 0.2 0.3
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prevalence of resistance of common urinary pathogens
against amoxicillin/clavulanic acid in our unit (>30% of
E. coli isolates are resistant against amoxicillin/clavulanic
acid) and many other centres precludes the empiric use of
this antimicrobial [27]. In the study by Hoberman et al.
[14], cefixime was administered orally for 14 days to 153
children younger than 2 years. The renal scarring assessed
at 6 months was lower, with 16.9% in patients having
lesions on acute-phase scintigraphy. These patients, how-
ever, had mild infection, as the mean initial CRP concen-
tration (11.9 mg/l) was low. In contrast, median CRP was
100 mg/l in our study, i.e. a 10-fold higher range, indicating
more pronounced inflammation, which, in turn, may
explain the higher rate of renal scarring. Also, Montini et
al. [21] reported an initial CRP concentration nine-fold
above the upper normal value, with a similar range of
scarring in children. Nevertheless, by bag urine collection,
they may have included children with false-positive urine
cultures, as urine collected by catheter was not a prerequi-
site for inclusion as in our study and the study by
Hoberman et al. [14]. Thus, compared with these two
studies, the reported study here included children with more
severe disease, covered a wider age range and renal scarring
was correlated to VUR per renal unit, and, most impor-
tantly, showed no difference for in- and out-patient
management, respectively. Overall, given the similar fre-
quencies of renal scarring after oral and sequential
intravenous/oral antimicrobial treatment in all three studies,
the oral-only regimen appears to be an alternative, offering
the benefits of out-patient management, including the
avoidance of painful and labourious intravenous approach
and the reduction of burdens on both parents and hospital
staff.
This study required the randomisation and enrolment of
a substantially larger number of patients than the number of
patients eventually qualifying for the analysis of renal
scarring. In agreement with the literature [5, 14, 21, 25],
one third of the enrolled patients showed no lesions in
acute-phase scintigraphy and were subsequently excluded
from follow-up analysis, as they are not at risk of renal
scarring [14, 15, 30]. In addition, almost one third of the
children with lesions in the acute-phase scintigraphy did not
undergo follow-up scintigraphy, primarily due to the
withdrawal of parental consent. Although this resulted in
a rather considerable reduction of the number of eventually
eligible patients, skewing of the study results is not likely.
The drop-outs were evenly distributed among the random-
isation groups and the participating centres. Nevertheless,
the relatively high number of drop-outs recorded in this
study may mirror the limited willingness of parents and
their children to participate in prospective clinical trials, in
particular, if the study lasts several months beyond the
acute phase of the illness and resolution of clinical
symptoms and includes procedures (e.g. injection of
radioactive substances, perceived as invasive by some
parents).
A further difficulty of the scintigraphy studies (including
the present research) is to make the distinction between
acquired renal scarring and congenital dysplasia in patients
with persistent photon defect on DMSA scintigraphy [9].
Without exact patient history or previous imaging, the
aetiology of scars cannot always be determined. To limit
this bias, renal scarring was defined in our study as
persistent or partially reversible lesions at the same location
of the lesion in the acute-phase scintigraphy. In addition,
renal ultrasound was not suggestive of renal dysplasia in
any of the patients.
In summary, our hypothesis was validated. Oral antimi-
crobial therapy with once-daily ceftibuten for 14 days, with
its attendant benefits, was shown to be equally as
efficacious as sequential treatment with intravenous cef-
triaxone for 3 days followed by 11 days of oral ceftibuten
for pyelonephritis in children.. The optimal duration of
antimicrobial therapy, however, and the role of oral regimen
in selected children (i.e. <6 months of age or with complex
urological malformations) [6] remain to be determined.
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